Looking at the quality adjusted life year

Michael Hiltzik of the LA Times recently took a look at a health plan that would look at the comparative effectiveness of drugs based on the length of treatment that might extend someone. So how would this cost effectiveness work? The NICE came up with a measurement known as QALY. This system looks at the length of time a person's life is extended as well as the quality of life they would have. It is measured on a scale from 0(death) to 1(complete health).

However, Haltzik brings up the fact that there would be a few downfalls to this system: 1) Society's aversion to placing a monetary value on life, 2) The lack of empirical basis for 30,000 pound standard and 3) Whose values are being measured, the patients, community or public?

Read the full article here. If you are interested in joining a group of professionals focusing on Value Driven Pharma, follow us on Twitter or join our LinkedIn group.

Share this article with your social network, just click below to share now!

Share |